Every 10-Q that Calidi Biotherapeutics, Inc. (CLDI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CLDI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CLDI filings page.
Calidi Biotherapeutics, Inc. reported a continued operating loss while restructuring its capital base for the quarter ended June 30, 2026. A 1-for-16 reverse stock split effective July 30, 2026 reduced outstanding common shares from 33,471,951 to approximately 2,092,023, with trading on a split-adjusted basis beginning July 31, 2026.
Total assets were $7.2 million, including cash of $4.1 million and restricted cash of $0.2 million. Total liabilities were $4.1 million, leaving total equity of $3.1 million. The company carries a $0.6 million promissory note at a 15% interest rate and warrant liabilities of $68 thousand.
For the three and six months ended June 30, 2026, net losses were $4.2 million and $8.3 million, respectively, compared with $5.8 million and $10.8 million in the prior-year periods, reflecting lower operating expenses. Net cash used in operating activities for the first half of 2026 was $8.5 million, versus $12.0 million a year earlier. The accumulated deficit reached $149.9 million.
Management states there is substantial doubt about the company’s ability to continue as a going concern within 12 months, given recurring losses, negative cash flows, and limited cash resources. To fund operations, Calidi recently raised capital through offerings including a March 2026 confidentially marketed public offering and at-the-market sales, and it expects to seek additional equity or debt financing.
Calidi Biotherapeutics reported another quarterly loss as it continues to develop its oncology platforms and has raised substantial doubt about its ability to continue as a going concern. For the three months ended March 31, 2026, the company recorded a net loss of $4.1 million, improving from a $5.1 million loss a year earlier as operating expenses declined.
Cash and restricted cash totaled $6.9 million at March 31, 2026, while operating activities used $4.1 million of cash in the quarter, highlighting limited runway. The company funded operations mainly through equity offerings, including a March 2026 marketed public offering, which helped increase total equity to $4.9 million. However, an accumulated deficit of $145.7 million and significant warrant overhang underscore its reliance on future capital raises.
Calidi Biotherapeutics (CLDI) filed its Q3 2025 report showing continued operating losses and a going concern warning. The company reported a Q3 net loss of $5.181M and a nine‑month net loss of $16.004M. Total operating expenses were $5.048M in Q3 and $15.774M year‑to‑date.
Liquidity remains tight. Cash was $10.375M as of September 30, 2025, with net cash used in operating activities of $16.249M for the nine months. The balance sheet listed total assets of $14.029M, total liabilities of $6.831M, and stockholders’ equity of $6.918M. Management stated there is “substantial doubt” about the company’s ability to continue as a going concern absent additional financing.
The company effected a 1‑for‑12 reverse stock split effective August 4, 2025; trading began on a split‑adjusted basis on August 5, 2025. As of November 10, 2025, 7,167,721 common shares were outstanding, excluding 150,000 non‑voting shares held in escrow. Year‑to‑date, financing activities provided $17.119M, including public offerings, a registered direct offering, and warrant‑related proceeds.
Calidi Biotherapeutics, Inc. reported continued operating losses, recording a net loss of $5.76 million for the quarter and $10.82 million for the six months ended June 30, 2025. The losses were driven by research and development and general and administrative expenses of $5.66 million for the quarter and $10.73 million for the six months. Loss per share was $1.99 for the quarter and $4.17 for the six months on weighted average shares of 2,877 and 2,569, respectively.
The company held $5.38 million of cash and restricted cash at period end after using $12.01 million of cash in operating activities during the six months. Total assets declined to $9.35 million and total liabilities declined to $7.28 million, leaving total equity of $2.08 million and an accumulated deficit of $132.4 million. Management discloses substantial doubt about the company’s ability to continue as a going concern within 12 months and intends to seek additional financing. During the period the company raised approximately $10.08 million from public and registered direct offerings and exercises, and recorded warrant liabilities totaling about $0.10 million. The company effected reverse stock splits (a prior 1-for-10 and a 1-for-12 reverse split) and retrospectively restated shares and per-share amounts for all periods presented.